SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
about
Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainMammalian COPII coat component SEC24C is required for embryonic development in miceThe multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsPhysiological and therapeutic regulation of PCSK9 activity in cardiovascular disease.Increased interaction with insulin receptor substrate 1, a novel abnormality in insulin resistance and type 2 diabetes.Cholesterol metabolism is altered in Rett syndrome: a study on plasma and primary cultured fibroblasts derived from patients.Absence of a red blood cell phenotype in mice with hematopoietic deficiency of SEC23B.The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.Neural tube opening and abnormal extraembryonic membrane development in SEC23A deficient mice.Pancreatic β cell enhancers regulate rhythmic transcription of genes controlling insulin secretionCOPII - a flexible vesicle formation systemGenetics. Simple genetics for a complex disease.New compounds able to control hepatic cholesterol metabolism: Is it possible to avoid statin treatment in aged people?Mea6 controls VLDL transport through the coordinated regulation of COPII assembly.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.PCSK9 targets important for lipid metabolismThe biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol.Mechanisms for exporting large-sized cargoes from the endoplasmic reticulum.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.Opening up new fronts in the fight against cholesterol.Endoplasmic Reticulum Stress and Ca2+ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism.Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture.The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.Epigallocatechin gallate induces an up-regulation of LDL receptor accompanied by a reduction of PCSK9 via the annexin A2-independent pathway in HepG2 cells.TFG facilitates outer coat disassembly on COPII transport carriers to promote tethering and fusion with ER-Golgi intermediate compartments.Dynamic Glycosylation Governs the Vertebrate COPII Protein Trafficking Pathway.Dimeric sorting code for concentrative cargo selection by the COPII coat.The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
P2860
Q27339783-33621585-E50B-4ED6-8FFD-A4D0CDB832C0Q28593531-4B9CDE66-8539-4EB7-AB6B-0189B97C4014Q30541820-142B2D3A-8034-4C11-9972-4AD3DBB0E474Q33599961-7DF6F7D4-4BD9-43E1-B8CF-5C9F450C75A6Q33646768-566C002B-BACC-4297-8C04-81F53A31F2AFQ34035419-CE785FD1-3BDC-4D9D-B431-F2C4671B2AF4Q34298053-48971A8B-3271-430A-87D4-A96DCE96389DQ34355679-06EC88AF-2AAE-4B3C-9061-B8B6C9EC068AQ34458693-2593F07D-25B1-4B64-BE56-42FD9EABCEC8Q35883857-92667DF8-3DBA-4F26-949B-1E5013CC4649Q36192465-BDA7AAAA-B93B-4D53-949D-B4DF9E3A741BQ36345553-11E0BA12-9CEA-431C-A377-B82403E1F455Q37078360-2BC37111-1C81-4BF7-BD92-A492A021618AQ37339090-7614A6CE-7ACB-4032-A058-2ECEF351F0AAQ37429025-E97DDC1A-15BC-4F39-82BA-4699F71478C0Q37457316-261EC543-CBE6-413F-889C-E30E7AA49F93Q37688760-A8311472-2918-4CE9-90EA-C22C4BC06937Q37693614-CA4DA7F8-E6EF-49AA-8103-8E92FB5DF3F3Q37703261-618DF1C2-8E98-4D2B-9955-63D51DC47CBEQ38151675-732AC5D0-5DB2-4C10-A4ED-F691A2E8564FQ38529922-996015D2-3806-4D1E-81E4-D32E9D29CD12Q39030028-239AACD5-8E91-43FF-9DC0-FCCDE03611B3Q39443793-034616D4-FEA6-417E-A889-850053F72F3FQ39739251-3DEDA7DC-E062-49F6-B218-9747CC60475EQ40445739-1A02A964-8C60-45A4-8DA3-AE1D6C7C5D29Q42131276-07248416-C9D5-4A7B-84E1-B0C7BBF21649Q42367561-12DD3541-5820-4873-AC47-D522C5C400FFQ42505455-DEEEC0BC-9680-47FB-BC48-6D149F9ACF98Q46017428-27BCB3A2-3A70-4A28-B548-E25C30D665F6Q47379003-7D87E28F-DC0A-4F08-86F7-8D6E2BDC4865Q52349856-B7C0DA5A-55C7-4017-B236-6E7793EA6C35Q58699073-F2E816BC-82E5-4E57-9037-A833164B1E74
P2860
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
@ast
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
@en
type
label
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
@ast
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
@en
prefLabel
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
@ast
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
@en
P2093
P2860
P50
P921
P3181
P356
P1433
P1476
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion.
@en
P2093
Andrea Baines
Elizabeth Adams
Genggeng Yu
Hui-Hui Liu
Jiandie Lin
Kanika Bajaj
Maureen A Sartor
Pengcheng Zhang
P2860
P304
P3181
P356
10.7554/ELIFE.00444
P407
P577
2013-04-09T00:00:00Z